ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

Summary

The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to 4 antiseizure medications yet still experiencing seizures.

Timeline

Start

2022-09

Primary completion

2024-09

Completion

2024-12

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications